TY  - JOUR
AU  - Shahar, T.
AU  - Rozovski, U.
AU  - Hess, K.R.
AU  - Hossain, A.
AU  - Gumin, J.
AU  - Gao, F.
AU  - Fuller, G.N.
AU  - Goodman, L.
AU  - Sulman, E.P.
AU  - Lang, F.F.
PY  - 2017//
TI  - Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival
T2  - Neuro Oncol
JO  - Neuro-Oncology
SP  - 660
EP  - 668
VL  - 19
IS  - 5
KW  - *glioblastoma
KW  - *mesenchymal stem cells
KW  - *microenvironment
KW  - *prognosis
AB  - Background: Human mesenchymal stem cells (hMSCs) have been shown to reside as stromal cells in human gliomas as glioma-associated hMSCs (GA-hMSCs), but their biological role remains unclear. Because recent evidence indicates that GA-hMSCs drive tumor cell proliferation and stemness, we hypothesized that a higher percentage of GA-hMSCs in tumors predicts poor patient prognosis. Method: We determined the percentage of cells coexpressing GA-hMSC markers CD105+/CD73+/CD90+ from patients with newly diagnosed high-grade glioma and analyzed the association between this percentage and overall survival (OS) in 3 independent cohorts: fresh surgical glioblastoma specimens (cohort 1, N = 9), cultured tumor specimens at passage 3 (cohort 2, N = 28), and The Cancer Genome Atlas (TCGA) database. Results: In all cohorts, patient OS correlated with the percentages of GA-hMSCs in tumors. For cohort 1, the median OS of patients with tumors with a low percentage of triple-positive cells was 46 months, and for tumors with a high percentage of triple-positive cells, it was 12 months (hazard ratio [HR] = 0.24; 95% CI: 0.02-0.5, P = .02). For cohort 2, the median OS of patients with tumors with a low percentage of GA-hMSCs was 66 months, and for tumors with a high percentage, it was 11 months (HR = 0.38; 95% CI: 0.13-0.9, P = .04). In the database of TCGA, the median OS times in patients with high and low coexpression levels of CD105/CD73/CD90 were 8.4 months and 13.1 months (HR = 0.4; 95% CI: 0.1-0.88; P = .04), respectively. Conclusions: The percentage of GA-MSCs inversely correlates with OS, suggesting a role for GA-MSCs in promoting aggressive behavior of gliomas.
SN  - 1522-8517
UR  - http://www.ncbi.nlm.nih.gov/pubmed/28453745
UR  - PM:28453745
N1  - PMID:28453745
ID  - Shahar_etal2017
ER  -